Webcast ImageWebcast
Medgenics Inc at UBS Global Healthcare Conference  (Replay)
05/25/16 at 8:00 a.m. ET
Medgenics Inc at UBS Global Healthcare Conference
Wednesday, May 25, 2016 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
12/22/15Medgenics Announces Annual Renewal of Rare and Orphan Disease Research Collaboration With The Children’s Hospital of Philadelphia
Annual option exercised to extend collaboration First development candidate advancing to Phase 2/3 development in 2016 Additional programs expected in 2016 PHILADELPHIA, Dec. 22, 2015 (GLOBE NEWSWIRE) --  Medgenics, Inc. (NYSE:MDGN) today announced the annual renewal of its major research collaboration with the Center for Applied Genomics (CAG) at The Children’s Hospital of Philadelphia (CHOP) focused on pediatric rare and orphan genetic diseases. The goal of the collaboration is to ... 
Printer Friendly Version
12/16/15Medgenics Announces Beta Thalassemia Research Program
PHILADELPHIA, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), today announced the initiation of a research program to evaluate the use of TARGTEPOTM alone or in combination with iron restriction to ameliorate erythropoiesis in Beta Thalassemia Intermedia (non-transfusion dependent thalassemia or NTDT) and Beta Thalassemia Major (transfusion dependent thalassemia or TDT). Dr. Stefano Rivella, Professor of Pediatrics and Ohene-Frempong Chair on Sickle Cell Anemia at The Childr... 
Printer Friendly Version
11/25/15Medgenics to Present at 27th Annual Piper Jaffray Healthcare Conference
PHILADELPHIA, Nov. 25, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), today announced that Michael Cola, President and CEO, will participate in a fireside chat discussion at the 27th Annual Piper Jaffray Healthcare Conference in New York. The event will take place at 3:30 p.m. ET on Wednesday, December 2, 2015 at the New York Palace Hotel. A live webcast of the presentation can be accessed under "Presentations" in the Investors section of the Company's website at www.medgenics.com... 
Printer Friendly Version
10/22/15Medgenics Reports Third Quarter 2015 Financial Results
Acquired Phase 2-Ready CNS asset, NFC-1 First of pipeline of potential programs from CHOP collaboration Results of Phase 1 GREAT trial to be presented at American Academy of Child and Adolescent Psychiatry (AACAP) meeting Completed Successful Public Offering for $46M in gross proceeds PHILADELPHIA, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) (the Company) today announced financial results for the three and nine months ended September ... 
Printer Friendly Version
10/15/15Medgenics to Host Conference Call to Announce Third Quarter 2015 Results on October 22, 2015
PHILADELPHIA, Oct. 15, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) will host a conference call and live audio webcast on Thursday, October 22, 2015 at 8:30 a.m. ET to discuss third quarter 2015 financial results. In order to participate in the conference call, please dial (844) 466-4113 (domestic) or (765) 507-2652 (international). The conference ID number is 61872467. The live webcast can be accessed under "Events" in the Investors section of the Company's website at www.medgen... 
Printer Friendly Version
10/13/15Medgenics Announces Key Appointments
PHILADELPHIA, Oct. 13, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN) today announced the following appointments: Liza Squires, MD joins as Vice President Research and Development, Therapeutic Area Head, Neuroscience David Fitts, PhD joins as Vice President and Head, Statistical Sciences and Data Management Stephen P. Spielberg, MD, PhD, joins Scientific Advisory Board "We are pleased to welcome Liza, David and Stephen to Medgenics. Their extensive experience ... 
Printer Friendly Version
10/12/15Medgenics Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock
PHILADELPHIA, Oct. 12, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN) today announced the completion of an underwritten public offering of 7,078,250 shares of its common stock, including 923,250 shares sold pursuant to the full exercise of an option previously granted to the underwriters to purchase additional shares of common stock. All of the shares were offered by Medgenics at a price to the public of $6.50 per share. The gross proceeds from this offering to Medgenics were approxima... 
Printer Friendly Version
10/01/15Medgenics Prices Public Offering of Common Stock
PHILADELPHIA, Oct. 1, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN) today announced the pricing of 6,155,000 shares of its common stock in a previously announced underwritten public offering at a price to the public of $6.50 per share. In connection with the offering, Medgenics has also granted the underwriters a 30-day option to purchase up to an additional 923,250 shares of its common stock. Gross proceeds to Medgenics from the sale of shares are expected to be approximately $40 mil... 
Printer Friendly Version
09/30/15Medgenics Announces Public Offering of Common Stock
PHILADELPHIA, Sept. 30, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. As part of this proposed offering, Medgenics intends to grant the underwriters a 30-day option to purchase up to an additional... 
Printer Friendly Version
09/09/15Medgenics Acquires Phase 2-Ready CNS Program: NFC-1
Strong Efficacy Signal Established in Genetically Identified Subset of ADHD Patients Development will Include Neuropsychiatric Symptoms of 22q11.2 Deletion Syndrome PHILADELPHIA, Sept. 9, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN) today announced the acquisition of neuroFix Therapeutics, LLC, the developer of NFC-1, a first-in-class, non-stimulant metabotropic glutamate receptor (mGluR) neuromodulator entering Phase 2/3 for the treatment of mGluR network mutation positi... 
Printer Friendly Version
09/03/15Medgenics to Present at 22nd Annual NewsMakers in the Biotech Industry Conference
PHILADELPHIA, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will present at BioCentury's 22nd Annual NewsMakers in the Biotech Industry Conference in New York, NY. The event will take place at 1:30 p... 
Printer Friendly Version
08/10/15Medgenics Reports Second Quarter 2015 Financial Results
Initiated enrollment in peritoneal dialysis study in U.S. Awarded $3.4 million grant from the Israeli Office of the Chief Scientist Advanced collaboration activities with CHOP PHILADELPHIA, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) (the Company), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of orphan diseases... 
Printer Friendly Version
07/15/15Medgenics Announces First Patient Enrolled in U.S.-Based Phase 2 Clinical Trial of TARGT-EPO for Treatment of Anemia in ESRD Patients Undergoing Peritoneal Dialysis
PHILADELPHIA, July 15, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that the first patient has been enrolled in its U.S.-based Phase 2 clinical trial of MDGN-201 (TARGTEPOTM), an investigational gene therapy for the treatment of anemia in end stage ... 
Printer Friendly Version
06/29/15Medgenics Added to RUSSELL 3000(R) and Global Indexes
PHILADELPHIA, June 29, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that it has been added to the Russell 3000® and Russell Global Indexes as part of Russell Investments' annual reconstitution that took place after market close on June 26, 2015.... 
Printer Friendly Version
06/17/15Medgenics to Present at JMP Securities Life Sciences Conference 2015
PHILADELPHIA, June 17, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will present at the JMP Securities Life Sciences Conference 2015 in New York, NY. The event will take place at 3:30 p.m. ET on Tuesday,... 
Printer Friendly Version
06/11/15Medgenics Awarded $3.4 Million Grant From the Israeli Office of the Chief Scientist
PHILADELPHIA, June 11, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that its wholly owned subsidiary, Medgenics Medical Israel Ltd. (MMI), was awarded a government grant of up to NIS 13.3 million (approximately USD 3.4 million) from the Office o... 
Printer Friendly Version
06/10/15Medgenics Announces Appointment of Barbara Duncan to Board of Directors
PHILADELPHIA, June 10, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced the appointment of Barbara Duncan to the Company's Board of Directors effective July 22, 2015. "We are very excited to welcome Barbara to our Board of Directors. She has pro... 
Printer Friendly Version
06/04/15Medgenics to Present Clinical Data at the 20th Congress of the European Hematology Association
- New Data Presented from Ongoing Phase 1/2 Study of TARGTEPOTM PHILADELPHIA, June 4, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that clinical data from the ongoing Phase 1/2 study of the Company's TARGTEPOTM (Transduced Autologous Restora... 
Printer Friendly Version
05/07/15Medgenics Announces Participation in Upcoming Conferences
PHILADELPHIA, May 7, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced its participation in the following upcoming conferences. American Society of Gene & Cell Therapy (ASGCT) 18th Annual Meeting in New Orleans, LA Clinical data from ... 
Printer Friendly Version
04/17/15Medgenics Reports First Quarter 2015 Financial Results
Commenced enrollment in mid-dose arm of MDGN-201 study Initiated peritoneal dialysis study in Israel Filed U.S. IND for TARGTEPO renal anemia programs Advanced collaboration activities with CHOP Progressed TARGTCNS program with Harvard University PHILADELPHIA, April 17, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) (the Company), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients ... 
Printer Friendly Version
04/02/15Medgenics to Host Conference Call to Announce First Quarter 2015 Results on April 17, 2015
PHILADELPHIA, April 2, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) will host a conference call and live audio webcast on Friday, April 17, 2015 at 8:30 a.m. ET to discuss first quarter 2015 financial results. In order to participate in the conference call, please dial (844) 466-4113 (domestic) or (765) 507-2652 (international). The conference ID number is 18428859. The live webcast can be accessed under "Events" in the Investors section of the Company's website at www.medgenics.... 
Printer Friendly Version
03/02/15Medgenics to Present at Upcoming Investor Conferences
PHILADELPHIA, March 2, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will present at two upcoming investor conferences. Details of the conferences are as follows: 27th Annual ROTH Conference in Dana P... 
Printer Friendly Version
02/13/15Medgenics Reports Fourth Quarter and Full Year 2014 Financial Results
Click here for PDF Click here for Word Proof of concept established for TARGTTM platform Enrollment initiated in mid-dose arm of MDGN-201 study; low-dose arm fully enrolled Preclinical peptide programs advancing Prioritizing CHOP collaboration programs PHILADELPHIA, Feb. 13, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) (the Company), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides i... 
Printer Friendly Version
01/30/15Medgenics to Host Conference Call to Announce Fourth Quarter and Full Year 2014 Results on February 13, 2015
Click here for PDF Click here for Word PHILADELPHIA, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) will host a conference call and live audio webcast on Friday, February 13, 2015 at 8:30 a.m. ET to discuss fourth quarter and full year 2014 financial results. In order to participate in the conference call, please dial (844) 466-4113 (domestic) or (765) 507-2652 (international). The conference ID number is 76989330. The live webcast can be accessed under "Events" in the... 
Printer Friendly Version
01/08/15Medgenics to Present at Biotech Showcase 2015 Conference
Click here for PDF Click here for Word PHILADELPHIA, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will present at the Biotech Showcase 2015 Conference in San Francisco, CA. The event will tak... 
Printer Friendly Version